Conference Coverage

Rheumatology patients seek guidance on CBD, cannabis products


 

FROM RWCS 2022

Overarching principles for medical cannabis in rheumatology

For the rheumatologist counseling a patient who either is self-medicating or wants to start using medical cannabis, the Canadian Rheumatology Association created overarching principles as part of their position statement to guide decision-making for clinicians.

First, clinicians should know that cannabis shouldn’t be used as an alternative treatment for standard of care in rheumatology, and the CRA noted that patients aged under 25 years should not use cannabis. CRA also recommended that clinicians try currently available treatment strategies for common reasons patients seek to use medical cannabis, such as pain relief or a sleep aid, before attempting to use medical cannabis. The CRA noted long-term effects of medical cannabis are not known for patients with rheumatic diseases.

In an interview, Arthur Kavanaugh, MD, professor of medicine at the University of California, San Diego, and director of RWCS, said that CBD and cannabis “come up quite frequently” at his clinic. “Many patients have already tried CBD, especially the topical formulation, prior to discussing it with me. In general, I do not dissuade patients from trying CBD, especially topical.”

Typically, he said his practice situation gives him access to a counselor from the anesthesia department with “significant expertise” in dosing and formulations. “It would be great if there were proper controlled trials of specific formulations to allow us to have real scientific data that may help the patients make optimal choices.”

One issue that is brought up by patients is cost. “These preparations can be relatively expensive,” Dr. Kavanaugh said, but noted that this is also a consideration when patients decide to use any therapy.

Dr. Troum reported having financial relationships with eight pharmaceutical companies.

Pages

Recommended Reading

OTC cannabidiol products tied to improved pain, sleep, anxiety
MDedge Family Medicine
Researchers eye cannabis for gynecologic pain
MDedge Family Medicine
Men with hypersexual disorder may have oxytocin overload
MDedge Family Medicine
Open-label placebo improves symptoms in pediatric IBS and functional abdominal pain
MDedge Family Medicine
Opioid exposure in early pregnancy linked to congenital anomalies
MDedge Family Medicine
Updated endometriosis guidelines emphasize less laparoscopy, more hormone therapy
MDedge Family Medicine
Potential new neuromodulation treatment for migraines
MDedge Family Medicine
Opioid deaths in North America predicted to soar
MDedge Family Medicine
‘Encouraging’ new national data on chronic pain management
MDedge Family Medicine
CDC releases updated draft guidance on opioid prescribing
MDedge Family Medicine